Attachment 31_R: Email Reminder 3 - 18

Form Approved
OMB No. 0910-0753
Exp. Date 09/30/2019
RIHSC No. 15-101CTP

Subject Line: FDA Health and Media Study Final Reminder

Please forward this email to [CHILD'S FIRST NAME OR INITIALS]:

Dear [CHILD'S FIRST NAME OR INITIALS]:

The fourth follow-up survey for the **FDA Health and Media Study** will be ending soon and we want to give you a chance to participate. Please consider completing the online survey on or before [date].

To complete the online survey on a personal computer, laptop, phone, or tablet, you must follow all three steps below:

1. **Open your web browser and type in the study website address: [RUSTEC WEBSITE]**
2. **Once you have reached the study website, type in the username and password exactly as shown below**

   Username: [Username]
   Password: [Password]

3. **Once you've typed in your username and password, you will see instructions for completing this round of the study.**

We will offer you a check for **$20** if you complete the survey by [date].

Your help with this round of the study is voluntary. All information that you provide will be kept private to the fullest extent allowable by law and used only for statistical purposes. You or your household will never be identified in any analysis, reports, or publications, and no one will try to sell you anything.

For more information about the study, you can call our project assistance line toll-free at (866) 214-2039, or email us at mediastudy@rti.org. If you have a question about your rights as a study participant, you can call RTI's Office of Research Protection toll-free at (866) 214-2043.

Thank you in advance for participating in this important research.

Sincerely,

Matthew Farrelly, PhD
RTI International

OMB No: 0910-0753 **Expiration Date: 09/30/2019**
Paperwork Reduction Act Statement: The public reporting burden for this collection of information has been estimated to average 5 minutes per response. Send comments regarding this burden estimate or any other aspects of this collection of information, including suggestions for reducing burden to PRAStaff@fda.hhs.gov.